ASC X的动态

Helping Develop #MedTech’s ASC Strategy: The shift of #musculoskeletal procedures to the #ASC has been increasing for the last decade. Today, over 25% of key MSK procedures are done in an ASC setting. As new procedures and surgical techniques are approved to be reimbursed in the ASC, rapid transitions have occurred. On an aggregate level, the rationale is clear: MSK MedTech companies should be thinking about optimizing their portfolio, sales and marketing, evidence generation, and other strategies to capitalize on this trend. That said, companies must be thoughtful in evaluating which specific procedures are shifting and where they are in the adoption cycle. Health Advances has access to proprietary claims data that covers over 300MM lives in the US and recently conducted a large ASC and Hospital Administration Survey to gather quantitative input on the shift. With data comes robust insight and strategy – let us help you navigate your ASC strategy. Jeffrey Abraham and I will be attending the Ortho Summit (OSET) next week in Las Vegas and would love to discuss this and a number of other trends we are seeing in the industry! #OSET24, #Musculoskeletal, #MSK, #ASC, #ASCSurvey

Join us tomorrow at our MedTech Theatre live presentation at MD&M West! Clifford Winterbottom and Ryan Thomson will be discussing “Healthcare Trends Driving Integration in Complex Surgical Devices” on Thursday, Feb 8th 11:30am. Included in discussion will be: Catheter Steering Technology - Flexible, Dexterous Devices at Millimeter Scales ? Using novel micromanufacturing techniques, creating dexterous steerable devices with smaller diameters and thinner walls than ever before. ? Intelligently micro-machined smart materials to create highly dexterous manipulators at millimeter and sub-millimeter scales. ? Improving therapeutic outcomes in complex flexible endoscopic procedures. ? Devices serve as adjuncts to standard, commercially-available endoscopic tools to augment performance improving quality of care with minimal workflow disruption. #mdmwest #imewest #steeringtechnology #enablingtechnologies #nisshamedical

We’re thrilled to share that our subsidiary,?Kardiolytics Inc, has been granted a new patent in the United States, marking a significant milestone in our journey towards revolutionizing cardiac care. The patent, numbered?US20240120110A1, recognizes our method of numerical modeling of blood flow in arteries—a vital component of our?#VCAST?technology. What does this mean for healthcare? ?? Our patented method allows for precise analysis of arterial blood flow, enabling clinicians to assess atherosclerotic plaque surface deformation and stress—an invaluable tool in diagnosing coronary artery disease. Przemek Tadla, CTO at?Medicalgorithmics?and COO at?Kardiolytics, shares his thoughts: “This new patent underscores the medical and commercial potential of the VCAST technology. It highlights our innovation and strengthens the competitive edge and protection of our technology.” But that’s not all! ?? We’re also making strides in regulatory approval processes. With?CE certification initiation?in the EU and plans for?FDA approval?in the US, we’re on track to bring VCAST to patients worldwide, offering a non-invasive, hospitalization-free diagnostic solution for coronary artery disease. Stay tuned as we continue to push the boundaries of innovation in cardiac care with VCAST technology: https://lnkd.in/eSMWKcts #Medicalgorithmics #VCAST #Innovation #CardiacCare #HealthTech

At Saints Sages Surgical, innovation is in our DNA. We don’t just follow trends or replicate what's already out there. We’re trailblazers, creating breakthrough solutions like our SA10 and SA100 systems—both globally unique and designed to set new standards in surgical energy technology. But we’re not stopping here. The future holds even more surprising and revolutionary products, designed to reshape the surgical landscape. We are continuously pushing the boundaries, driven by the belief that innovation is the key to improving patient outcomes and empowering surgeons with cutting-edge tools. We invite surgeons and business partners to join us on this exciting journey. By combining your expertise with our powerful R&D capabilities, together we can develop game-changing solutions that truly benefit patients and transform surgical care. Stay tuned—because at Saints Sages, innovation never rests. #Innovation #SurgicalExcellence #CuttingEdge #Partnership #SaintsSagesSurgical #SA10 #SA100

?? ?????? ?????????????? ?????????? We are excited to unveil our brand-new CASIA2 User Experience #brochure! ?? Do you want to see how CASIA2 Cornea / Anterior Segment #OCT is transforming ophthalmic care? Gain valuable insights from real-life cases shared by eye care professionals. ?? What’s inside? ?? Patient experiences ?? Clinical outcomes ?? Versatility & benefits of CASIA2 #ASOCT ?? Don’t miss out on this comprehensive guide to how #CASIA2 is making a real difference in #eyecare. Download your copy now and get inspired by these success stories. ?? Download it from the #TOMEY blog: https://lnkd.in/dgDSbWdx

?????????? ?????????????? ???????? ???????? ?????? ?? ????????-???????????????? ?????????????? ?? Today marks a significant milestone as Johnson & Johnson MedTech announces its planned acquisition of V-Wave, a pioneer in heart failure treatment, for $600 million, with potential milestone payments reaching up to $1.1 billion. V-Wave’s Ventura Interatrial Shunt (IAS) is a groundbreaking, minimally invasive solution designed to bring hope to the 800,000 U.S. patients who battle heart failure with reduced ejection fraction (HFrEF) each year. By effectively reducing elevated left atrial pressure, this innovative device addresses a critical need in cardiovascular care. This acquisition not only strengthens J&J’s cardiovascular portfolio but also reaffirms its mission to deliver smarter, less invasive treatments. With an FDA Breakthrough Device Designation and CE mark already secured, the potential for the Ventura IAS to change lives is immense. For those in the medical device industry, this is a testament to the power of innovation and collaboration in addressing some of the most pressing healthcare challenges. Excited to see how V-Wave's cutting-edge technology will flourish as part of the J&J family! #MedTech #HealthcareInnovation #Cardiovascular #HeartFailure #JohnsonAndJohnson #VWAVE #MedicalDevices

The Patient Care Journey module from AcuityMD is set to revolutionize how MedTech can positively impact patient care. Complete game changer! ??

Exciting news in the medical tech world! Philips, renowned for pioneering health technology, has made a leap in treating chronic venous insufficiency (CVI). The first patient has welcomed their innovative Duo Venous Stent System, with FDA's nod of approval. ???? Venous outflow obstruction has long been a challenge for 25 million individuals worldwide. Dr. Erin Murphy, armed with the Duo system at Sanger Heart & Vascular Institute, has successfully delivered hope outside trial settings. This duo stent design cleverly addresses both flexibility and compression resistance, a real game-changer in vascular intervention! ?? Key study, VIVID, reports astounding results - a 90.2% effectiveness in primary patency and a primary safety endpoint at an impressive 98.7%. Participants saw marked improvements in quality of life, a testament to Duo's potential! ??? In the toolboxes of vascular experts, Duo stands out as more than a stent; it's an advancement that pairs seamlessly with IVUS technology. Expect exceptional outcomes and enhanced quality of life, as Philips continues to improve patient care one innovation at a time. ?? #Philips #CVI #MedicalInnovation

We're just a few weeks away from the Fall IDN Summit & Reverse Expo! Be sure to find Andrew DeLeeuw and Joe Bothwell to learn how DOCSI makes surgical supply chain optimization a breeze through scalable physician engagement. #DOCSI #IDNSummit